A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION, THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13), OR PCV13 FOLLOWED BY PPV23 IN BRAZIL

被引：1

作者：

Jiang, Y. ^{[1
]}

Yang, X. ^{[2
]}

Petigara, T. ^{[2
]}

Chabrol Haas, L. ^{[3
]}

Graham, J. ^{[4
]}

机构：

[1] Merck Sharp & Dohme Ltd, Hoddesdon, Herts, England

[2] Merck & Co Inc, Kenilworth, NJ USA

[3] MSD Brazil, Sao Paulo, SP, Brazil

[4] RTI Hlth Solut, Durham, NC USA

来源：

VALUE IN HEALTH | 2017年 / 20卷 / 09期

关键词：

D O I：

10.1016/j.jval.2017.08.2909

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PIN24

引用

页码：A930 / A930

页数：1

共 50 条

[1] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
Prieto, E.
Jiang, Y.
Yang, X.
Graham, J. B.
Monsanto, H.
Ruiz, J.
Beltran, C.
Rojas, M.
[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
[2] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
Wu, D. B. C.
Chang, C. J.
Chien, L.
Fang, H. C. H.
Roberts, C. S.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
[3] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
Dorange, A.
Nyman, L.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
[4] ASSESSING THE COST-EFFECTIVENESS (CE) OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC) IN THE UK
Jiang, Y.
Gauthier, A.
Keeping, S. T.
Carroll, S. M.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A396 - A397
[5] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN BRAZIL
Fujii, R. K.
Mould, J. F.
Presa, J.
Jardim, E.
Sato, R.
Strutton, D. R.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
[6] A BUDGET IMPACT (BI) ANALYSIS OF VACCINATING THE ELDERLY AND AT-RISK ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO NO VACCINATION (NOVAC) OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN THE UK
Jiang, Y.
Gauthier, A.
Keeping, S. T.
Carroll, S. M.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A388 - A388
[7] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
Jiang, Y.
Gauthier, A.
Annemans, L.
van der Linden, M.
Nicolas-Spony, L.
Bresse, X.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
[8] Immunological efficacy of a prime-boost vaccine strategy combining the 13-valent Pneumococcal Conjugate Vaccine (PCV13) followed by the 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) versus PPV 23 alone in HIV-infected adults
Sadlier, C.
Conlon, N.
Rock, C.
Brown, A.
O'Dea, S.
Dunne, J.
Bergin, C.
[J]. HIV MEDICINE, 2014, 15 : 5 - 6
[9] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN SAO PAULO STATE, BRAZIL - PUBLIC PERSPECTIVE
Fujii, R. K.
Roberts, C. S.
Mould, J.
Presa, J.
Jardim, E.
Manfrin, D. F.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A397 - A397
[10] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN GERMANY
Jiang, Y.
Gauthier, A.
Annemans, L.
van der Linden, M.
Nicolas-Spony, L.
Bresse, X.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A279 - A279

← 1 2 3 4 5 →